Bringing you the Best Analytical Legal News
The transaction involves a primary investment for a aproximate 5% stake in Axis Finance, a systemically important NBFC, and includes structuring, regulatory advisory, and multi-practice due diligence.
The transaction marks a significant cross-border healthcare deal involving a global pharmaceutical portfolio spanning women’s health, biosimilars, and specialty therapies.
The investment, announced on November 25, was made by funds managed by KKR along with participation from new investor PSP Investments of Canada, reinforcing confidence in India’s education sector.
by Kshitij Nair* and Khushi Agarwal**
by Ketki Kulkarni*